CagriSema 2026: Weight Loss Results, FDA Timeline & Why You Can't Buy It Yet

CagriSema is an investigational weekly injection combining cagrilintide and semaglutide.

In REDEFINE 1, adults without diabetes lost an average of 20.4% of their body weight at 68 weeks under the treatment-policy analysis, or 22.7% under the trial-product analysis.

Those are two estimates from the same trial, not two different doses or a promise of individual results. Read the original REDEFINE 1 report.

CagriSema is not FDA-approved. Novo said on September 30, 2026 that it expected a US decision in Q4 2026.

A projected decision is not an approval or launch date. The useful questions are what each trial measured, how it compared directly with tirzepatide, and what access is actually available.

What is CagriSema?

CagriSema combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist.

REDEFINE 1 and 2 investigated a once-weekly subcutaneous combination targeting 2.4 mg of each ingredient, with protocol flexibility for tolerated doses.

It is a different investigational product from semaglutide alone. The REDEFINE 1 paper describes its formulation and study design.

The combination targets two appetite-related pathways. That explains the research question, not a guaranteed clinical advantage for every person.

The relevant evidence comes from the actual trial arms and analyses below, rather than an assumption that adding a receptor target always improves treatment.

What did REDEFINE 1 and 2 find?

Both trials measured outcomes at 68 weeks, but they studied different populations.

Keep the population and analysis beside the percentage: REDEFINE 1 enrolled 3,417 adults without diabetes; REDEFINE 2 enrolled 1,206 adults with type 2 diabetes.

The treatment-policy analysis estimates the effect of assignment to treatment regardless of discontinuation or other weight-loss treatment. The trial-product analysis estimates use as intended without those events.

Both are clinical-trial estimates. Neither is an observed real-world effectiveness rate, and the higher figure does not mean every participant stayed on the maximum dose.

REDEFINE 1 also compared the combination with its individual ingredients in the same study.

Under the treatment-policy analysis, mean weight reduction was 20.4% with CagriSema, 14.9% with semaglutide, 11.5% with cagrilintide and 3.0% with placebo.

These within-trial comparisons are more informative than placing unrelated headline results side by side.

The different REDEFINE 1 and 2 populations do not establish that diabetes itself caused the difference between their results.

What did the women and menopause analyses show?

The women-specific analysis estimated 25.0% mean weight loss with CagriSema and 3.0% with placebo at 68 weeks. This was an exploratory post hoc analysis of REDEFINE 1, not a trial of an approved menopause treatment.

It studied the once-weekly subcutaneous combination of cagrilintide 2.4 mg and semaglutide 2.4 mg in adults with overweight or obesity without diabetes. Read the original conference abstracts P-50 and P-51.

Novo's October 20 announcement describes 2,309 women across all four trial arms.

The CagriSema-versus-placebo comparison below used 1,441 and 461 women, respectively: 1,902 in total. The menopause analysis divided those comparison groups by reproductive stage or hormone-therapy use.

These are different denominators, not 2,309 women all receiving CagriSema.

The table reports 68-week trial-product, or efficacy-estimand, estimates assuming continued treatment without other weight-loss therapies.

Menopause groups were assigned after the trial using age, medical history and symptoms, rather than prospectively collected staging or biochemical confirmation.

Novo reports no formal treatment-by-sex or treatment-by-subgroup interaction test.

Numerical differences between rows do not establish that menopause or hormone therapy caused a different response. Source and analysis limitations.

Novo Nordisk funded both analyses. They are hypothesis-generating, not evidence that women should change treatment or that CagriSema outperforms tirzepatide in this population. The direct comparison below is a separate trial.

CagriSema remains investigational; the pipeline overview separates research milestones from current access.

How did CagriSema compare with Zepbound?

In the 84-week, open-label REDEFINE 4 trial involving 809 adults, CagriSema did not meet the prespecified noninferiority criterion against tirzepatide, the ingredient in Zepbound. Novo's February 23, 2026 announcement reported a lower mean reduction with CagriSema under both analyses:

Failure to meet noninferiority is not the same statement as proving one medicine is the right choice for every patient. Nor does this announcement settle the FDA's decision.

Novo says the US application is based on REDEFINE 1 and 2; the regulator determines the application's outcome.

What side effects were reported?

Gastrointestinal adverse events were common in REDEFINE 1: the paper reports them in 79.6% of the CagriSema group, 73.8% of the semaglutide group and 39.9% of the placebo group.

These are trial-specific rates, not the likelihood for a particular patient or evidence about a compounded product. The original paper provides the event definitions and safety tables.

Benefits and adverse events need to be considered together. The study's flexible dosing and selected population matter when interpreting the results.

An investigational trial does not provide an approved prescribing dose or replace a clinician's assessment.

When could CagriSema be approved in the US?

Novo's September 30 announcement says it submitted the US application in December 2025 and expected a decision in the fourth quarter of 2026. The release gives a quarter, not an exact FDA action day or a guaranteed approval.

It also does not establish when a commercial prescription would become available. Check the dated sponsor announcement rather than treating a forecast as an approval.

Can you buy or compound CagriSema now?

There is no FDA-approved CagriSema product for routine US prescribing. FDA also states that cagrilintide cannot currently be used in compounding under federal law.

A seller using the name CagriSema does not establish that its product is the formulation studied in REDEFINE or that it has the same quality, dosing or outcomes. FDA explains its concerns about unapproved GLP-1 products.

What can you discuss with a clinician instead?

Whether to start treatment, continue a current medicine or wait is an individual clinical decision.

Approved medicines and compounded preparations are different products; results for branded trial treatments do not establish outcomes for a provider's compounded preparation.

Our next weight-loss drugs overview separates development milestones from current access, and our retatrutide guide explains the separate triple-agonist program.

• •For current branded pathways and separate medication/membership charges, read the Hers review and Hers pricing guide.
• •For an approved oral medicine, see Foundayo's access and price guide.
• •For program features and the limits of compounded care, read the Embody review and Enhance MD review. Neither establishes equivalence with CagriSema.
• •Use the cost calculator for a scenario budget or the program match quiz for program features, not a treatment recommendation.
• •If paying from a tax-advantaged account, check our HSA/FSA payment checklist. Acceptance of a card does not establish eligibility for every charge.

Sources